Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Palvella Therapeutics, Inc. - Common Stock (NQ: PVLA )

26.77 -0.41 (-1.51%)
Streaming Delayed Price Updated: 2:17 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,252
Open 27.18
Bid (Size) 26.78 (1)
Ask (Size) 27.00 (2)
Prev. Close 27.18
Today's Range 26.14 - 28.00
52wk Range 11.17 - 29.27
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pavella - Undiscovered Biotechnology Stock
The company focuses on developing therapies for rare genetic skin diseases, with its lead product QTORIN rapamycin in advanced clinical trials. 
Via Talk Markets
Topics Stocks / Equities
Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
From Palvella Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+123.08%
+123.08%
1 Month
+65.76%
+65.76%
3 Month
+108.65%
+108.65%
6 Month
+108.65%
+108.65%
1 Year
+108.65%
+108.65%

More News

Read More
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
From Palvella Therapeutics Inc.
Via GlobeNewswire
This Intuitive Machines Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
From Palvella Therapeutics Inc.
Via GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
From Palvella Therapeutics Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.